You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
国药中国生物预期今年新冠疫苗产能可达10亿剂以上
阿思达克 02-08 12:31
国药集团中国生物技术董事长杨晓明表示,预计今年公司新冠疫苗的产能可达10亿剂以上,助力全球疫苗公平分配,从企业的角度讲,就是在安全规范的前提下更多、更快生产出高质量的疫苗。

他指,目前国药集团中国生物新冠灭活疫苗已在匈牙利、塞舌尔、巴基斯坦、摩洛哥等十多个国家和地区获批紧急使用,在阿拉伯联合酋长国、巴林注册上市,在中国获批附条件上市。

他表示,现在研发生产工艺与几十年前的灭活疫苗工艺已经完全不一样了,可以说是脱胎换骨的变化——工艺上有提升、技术上有突破,采用了先进的细胞培养技术、纯化工艺技术等,生产效率高,质量控制指标已达到国际先进水平。

他又指,目前国药集团中国生物等生产的国产疫苗出口供应的国家多为发展中国家,这些国家基本没有能力研发或生产新冠疫苗,相比其他国家更需要疫苗,中国企业正为促进疫苗公平分配尽应尽的义务。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account